Back to Journals » Drug Design, Development and Therapy » Volume 13

A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson’s disease, in healthy volunteers
Total article views | Abstract views | HTML views | PDF downloads | Totals | |
---|---|---|---|---|---|
6,021 | Dovepress* | 4,251 | 1,095+ | 1,024 | 5,346 |
PubMed Central* | 0 | 675 | 174 | 675 | |
Totals | 4,251 | 1,770 | 1,198 | 6,021 | |
*Since 29 March 2019 +Since July 2016 |
Total mentioned | Delicious | Others | |||
---|---|---|---|---|---|
2 | 0 | 0 | 0 | 1 | 1 |
View citations on PubMed Central and Google Scholar